1	IN THE UNITED STATES DISTRICT COURT		
2	FOR THE NORTHERN DISTRICT OF CALIFORNIA		
3	EUREKA DIVISION		
4	Impax Laboratories, Inc.,	Civ. No. 3:11-mc-80206-JSW (NJV)	
5	Plaintiff,	STIPULATION AND ORDER COMPELLING MCKESSON	
6	v.	CORPORATION'S COMPLIANCE WITH SHIRE LLC'S SUBPOENA	
7	Shire LLC,	Hearing Date: October 11, 2011	
8	Defendant,	Time: 11:00 AM	
9	and	Courtroom: Eureka Judge: Magistrate Judge Vadas	
10	Teva Pharmaceuticals USA, Inc.,		
11	Intervenor-Defendant.		
12	THIS MATTER comes before the Court	on Shire LLC's ("Shire") Fed. R. Civ. P. 37	
13	Motion to Compel McKesson Corporation's Compliance with Subpoena to produce documents		
14	and designate a corporate witness(es) for deposition in a civil action pending in United States		
15	District Court for the Southern District of New York, <i>Impax Laboratories</i> , <i>Inc. v. Shire LLC</i> ,		
16	Civ. No. 1:10-cv-08386 (MGC) (AJP) (S.D.N.Y.) (the "New York litigation").		
17	The parties, having come to an agreement, request that the Court enter the following		
18	Stipulation and Order:		
19	McKesson Corporation ("McKes	son") shall make best efforts to produce the	
20	following documents and things from its San Fra	ancisco, CA employees by October 7, 2011 and	
21	from all other McKesson employees by October	14, 2011. McKesson shall produce documents	
22	from January 1, 2009 to the present:		
23	a. McKesson's communicat	ions with Shire, Impax and Teva regarding	
24	generic Adderall XR® and McKesson's internal	documents (e.g., memoranda, e-mails)	
25	concerning those communications, including:		
26	i. Offers from and n	egotiations with Shire, Impax and Teva,	
27	including pricing details (both offered and actua	l), discounts, rebates, incentives, etc. offered	
28	and/or paid by Shire, Impax and Teva;		

1	ii. Forecasts exchanged with Shire, Impax and Teva; and		
2	iii. McKesson's internal documents concerning how or why it chose		
3	one supplier over another.		
4	b. Documents concerning Impax's and Teva's inability to supply or		
5	interruptions/delays in its supply of generic Adderall XR, including cancellation of orders.		
6	c. Data reflecting McKesson's purchases of branded and generic Adderall		
7	XR.		
8	d. Data reflecting McKesson's inventory levels of branded and generic		
9	Adderall XR.		
10	e. Documents concerning general shortages in the availability of branded		
11	and generic Adderall XR <sup>®</sup> .		
12	f. Documents concerning any penalties or repercussions for Impax's		
13	inability to supply generic Adderall XR <sup>®</sup> , including loss of goodwill.		
14	g. Documents concerning any restrictions placed on how much branded and		
15	generic Adderall XR McKesson could purchase and warehouse (i.e., would it purchase as much		
16	as it could, limited only by shelf space, tied to patient demand, etc.).		
17	2. In connection with McKesson's search for documents responsive to the categories		
18	identified in paragraph 1, it is understood that McKesson will gather documents from the key		
19	company representatives that are associated with managing the purchase of branded and generic		
20	0 Adderall XR.		
21	3. McKesson shall make its best efforts to make a corporate witness(es) available		
22	for deposition at a mutually acceptable time and place for deposition on or before October 31,		
23	2011 to testify as to the following topics:		
24	a. The authenticity of documents produced in response to Shire's subpoena		
25	and this order ("Subject Documents").		
26	b. McKesson's retention policies with respect to the Subject Documents.		
27	c. McKesson's efforts to locate and produce the Subject Documents.		
28			

1	d. Whether the Subject Documents constitute records of regularly conducted		
2	activity according to Rule 803(6) of the Federal Rules of Evidence.		
3	e. Each witness's education and work experience, including information		
4	about the witness's duties and responsibilities when working for or on behalf of McKesson.		
5	f. McKesson's purchases of Adderall XR and generic Adderall XR,		
6	including McKesson's negotiations with Shire, Impax, and Teva and McKesson's decision to		
7	award "one-stop" status to Teva.		
8	g. McKesson's inventory levels of Adderall XR and generic Adderall XR.		
9	h. Shortages in the availability of branded and generic Adderall XR®.		
10	i. Any penalties or repercussions, including loss of goodwill, suffered by		
11	Impax due to its inability to supply Adderall XR <sup>®</sup> .		
12	j. Any restriction on how much branded or generic Adderall XR McKesson		
13	could purchase and warehouse.		
14	k. Orders received from and sales by McKesson to its customers for branded		
15	and generic Adderall XR, including generic erosion and rates of generic purchasing.		
16	IT IS SO STIPULATED AND ORDERED.		
17	Dated: September 27, 2011		
18			
19			
20	Peter W. Craigie, State Bar No. 99509 Craigie, McCarthy & Clow Steven Winick, State Bar No. 160815 Brian R. Blackman, State Bar No. 196996		
21	540 Pacific Avenue Sheppard, Mullin, Richter & Hampton LLP San Francisco, California 94133 Four Embarcadero Center, 17 <sup>th</sup> Floor		
22	Telephone: 415-732-7788 San Francisco, CA 94111 Facsimile: 415-732-7783 Telephone: 415-434-9100		
23	E-mail: peter@cmclawpartners.com Facsimile: 415-434-3947 E-mail: shwinick@sheppardmullen.com		
24	Edgar H. Haug E-mail: brblackman@sheppardmullin.com Steven M. Amundson		
25	Michael F. Brockmeyer Attorneys for Nonparty David A. Zwally McKesson Corporation		
26	David Herman John G. Taylor		
27	Frommer Lawrence & Haug LLP 745 Fifth Avenue		
28	New York, New York 10151 Telephone: 212-588-0800		
	Facsimile: 212-588-0500		

Document Prepared on Recycled Paper

## Case3:11-mc-80206-JSW Document11 Filed09/27/11 Page4 of 4

1	E-mail: ehaug@flhlaw.com E-mail: samundson@flhlaw.com E-mail: mbrackmayar@flblay.com
2	E-mail: mbrockmeyer@flhlaw.com E-mail: dzwally@flhlaw.com E-mail: dherman@flhlaw.com
	E-mail: jtaylor@flhlaw.com
4	Attorneys for Defendant
5	Shire LLC
6	PURSUANT TO STIPULATION IT IS SO ORDERED
7	
8	ESTATES DISTRICT CO
9	Dated: September 27, 2011
10	By:  NANDOR J. VADAS  NANDOR J. VADAS
11	United States Magistrate Judge
12	
13	
14	
15	
16	
<ul><li>17</li><li>18</li></ul>	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
,	